Emily Pittman

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

Assuntina G. Sacco, Ruifeng Chen, Francis P. Worden et al. · The Lancet Oncology · 2021 · 258 citations · Full text

Medicine, Oncology, Cancer Pharmacology +10

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

Michael Y. Choi, George F. Widhopf, Emanuela M. Ghia et al. · Cell stem cell · 2018 · 187 citations · Full text

Medicine, Immunology, Oncology +16

Research-based PAM50 signature and long-term breast cancer survival

Minya Pu, Karen Messer, Sherri R. Davies et al. · Breast Cancer Research and Treatment · 2019 · 110 citations · Full text

Medicine, Cancer Biology, Oncology +17

Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

Stephen Ryan, Jing Zhang, Danielle Burner et al. · Journal of Translational Medicine · 2020 · 32 citations · Full text

Medicine, Immunology, Oncology +17

Isolation and Structure Determination of Malevamide E, a Dolastatin 14 Analogue, from the Marine Cyanobacterium <i>Symploca laete-viridis</i>

B O Adams, Peter Pörzgen, Emily Pittman et al. · Journal of Natural Products · 2008 · 30 citations

Life Sciences, Biochemistry, Microbiology +16